www.nanomedinc.com

1
Carbon Nanotube-Based Cancer Therapeutics
Medical Nanotechnologies Incorporated
Rob Burgess, Ph.D.Founder and President
www.nanomedinc.com
2
Zyvex Corporation and Zyvex Performance Materials
Carbon Nanotube Functionalization
3
Zyvex Performance Materials Technical Approach
Zyvex NanoSolve Enhanced Composites

• Sizing agent or tailored coupling agent
• Exfoliation of CNT
• Uniform dispersion
• Adhesion to polymer
• Not a surfactant
• Other advanced capabilities
• Process knowledge
• Custom formulations

• Two distinct functions
• Non-damaging binding to the CNT
• Customizable adhesion to host material (example
  polymer such as epoxy)

Kentera Technology Enables CNTs in
Composites
4
Kentera-Conjugated Carbon Nanotubes are Soluble
in Water

• Customizable side chains confer solubility

5
RF-mediated CNT Thermal Conductivity
RF field
RF Transmitter
RF Receiver
Target area
CNT-introduced regions
Source Adapted from US Patent Application
2005/0251234 A1 Inventors Kanzius et al.
Source Gannon et al.
6
CNT Functionalization
Carbon nanotubes can be functionalized with
antibodies and polar lipids.
AFM
AFM
TEM
Source Chakravarty et al.
Source Marches et al.
7
Intracellular Accumulation of PEDOT/PSS-Conjugated
Carbon Nanotubes
CNT Intracellular Delivery
HEK293 Cells
72 hours post-treatment
Source Draper et al.
8
Carbon nanotube properties make them a unique
platform for therapeutic applications.

• Organized Structure
• Mechanism of Action Known
• RF and Near IR Sensitive
• Electrically and Thermally Conductive
• Can be Functionalized with a Variety of Molecules
• Can Penetrate Cells

9
Kentera and Kentera-conjugated carbon nanotubes
are minimally cytotoxic.
CNT Cytotoxicity
Source Draper et al.
10
Antibody/CNT Cell Surface Binding and Cytotoxicity
Antibody/lipid-coated carbon nanotubes are
noncytotoxic and bind specifically to cancer
cells.
Daudi Cells
Source Chakravarty et al.
Source Marches et al.
11
Cell Surface Binding
Antibody-coated carbon nanotubes bind
specifically to cancer cells.
Source Chakravarty et al.
12
CNT- Based Cancer Therapeutics
Cancer cells are effectively ablated by carbon
nanotubes in the presence of NIR light.
Source Chakravarty et al.
13
Panc-1 cells containing Kentera-conjugated carbon
nanotubes are efficiently ablated upon RF
exposure.
CNT- Based Cancer Therapeutics
No SWNTs 11 PI Stained
SWNTs 99.7 PI Stained
Source Gannon et al.
14
Intratumoral CNT/Kentera injections demonstrate
RF-mediated cellular ablation.
Kentera/SWNTs
Kentera
HE
TUNEL
Source Gannon et al.
15
Proposed Product Pipeline Moving Towards
Targeting CNTs
Monoclonal Antibody Cell Surface Breast, Colorectal, Head and Neck Her2, Erbitux
Small Molecule Cell Surface, Intracellular Lung Tarceva, Iressa
Aptamer Cell Surface, Intracellular Renal, Lung AS1411 (in dev.)
Peptide Cell Surface, Intracellular Breast, Thyroid RGD (in dev.)
Targeting Agent Mode of Action Cancer Application Known Example(s)
16
Criteria for Success Targeted CNT Cancer
Therapeutics

• Functionality
• Dispersion - Effective aqueous dispersion must be
  demonstrated.
• Efficacy CNTs must aggressively ablate
  targeted tissue.
• Toxicity CNTs and polymer functionalization
  must be demonstrated as nontoxic.
• Specificity CNTs must be successfully targeted
  to tumorigenic tissue and away from healthy
  tissue.

17
Acknowledgments
UT-Dallas Rocky Draper, Ph.D. Paul Pantano,
Ph.D. Inga Musselman, Ph.D.
Zyvex Corporation Jim Von Ehr Gareth Hughes,
Ph.D. Tanja Kmecko
UT-MD Anderson Cancer Center Steve Curley, M.D.
UT-SW Medical Center Ellen Vitetta, Ph.D. Radu
Marches, Ph.D. Pavitra Chakravarty, Ph.D.
Nanoco, LLC Peter Wilk, M.D.
18
For Further Information
Rob Burgess, Ph.D. President Medical
Nanotechnologies, Inc. Email rob.burgess_at_nanomed
inc.com Phone [phone] www.nanomedinc.com